MALLINCKRODT PLC (MNK) Stock Price, Forecast & Analysis
USA - NYSEARCA:MNK - IE000O3L0NQ3 - Common Stock
MNK Key Statistics, Chart & Performance
The current stock price of MNK is 0.3402 USD. In the past month the price decreased by -68.5%.
MNK Latest News, Press Relases and Analysis
MNK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 39.24 | 816.66B | ||
| JNJ | JOHNSON & JOHNSON | 18.2 | 454.86B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.56 | 255.48B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.83 | 239.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.81 | 219.77B | ||
| MRK | MERCK & CO. INC. | 9.87 | 214.76B | ||
| PFE | PFIZER INC | 7.27 | 140.15B | ||
| SNY | SANOFI-ADR | 11.52 | 123.27B | ||
| GSK | GSK PLC-SPON ADR | 7.73 | 94.25B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.02 | 93.77B | ||
| ZTS | ZOETIS INC | 23.17 | 63.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48 | 42.45B |
Related stock screener links
About MNK
Company Profile
Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. The firm operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The firm focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.
Company Info
MALLINCKRODT PLC
College Business & Technology Park, Cruiserath,, Blanchardstown
DUBLIN D15 IE
CEO: Mark C. Trudeau
Employees: 2700
MALLINCKRODT PLC / MNK FAQ
Can you describe the business of MALLINCKRODT PLC?
Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. The firm operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The firm focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.
What is the current price of MNK stock?
The current stock price of MNK is 0.3402 USD. The price decreased by -14.97% in the last trading session.
What is the dividend status of MALLINCKRODT PLC?
MNK does not pay a dividend.
What is the ChartMill rating of MALLINCKRODT PLC stock?
MNK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is MALLINCKRODT PLC (MNK) stock traded?
MNK stock is listed on the NYSE Arca exchange.
What is the employee count for MNK stock?
MALLINCKRODT PLC (MNK) currently has 2700 employees.
MNK Technical Analysis
MNK Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |